[Anti-TNF alpha in the treatment of psoriatic arthritis].

Abstract

Psoriatic arthritis is an inflammatory and possibly destructive form of arthritis. As in rheumatoid arthritis and ankylosing spondylitis, the use of biological therapy in psoriatic arthritis is a therapeutic revolution: both articular and cutaneous efficacy have been shown, and some improvement is visible on radiography. The benefit-risk ratio will improve when we learn to identify more accurately the patients likely to benefit from these treatments.

• Authors: Pascal Claudepierre, Daniel Wendling, Jean-David Cohen
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 35 Issue 4 Pt 2 Pg. 647-55 (Apr 2006) ISSN: 0755-4982 [Print] France
• Vernacular Title: Anti-TNF alpha dans le traitement du rhumatisme psoriasique.
• PMID: 16614610 (Publication Type: Comparative Study, English Abstract, Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antirheumatic Agents
• Dermatologic Agents
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor-alpha
• Infliximab
• Adalimumab
• Etanercept

Topics

• Adalimumab
• Algorithms
• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antirheumatic Agents (administration & dosage, therapeutic use)
• Arthritis, Psoriatic (diagnosis, drug therapy)
• Dermatologic Agents (administration & dosage, therapeutic use)
• Etanercept
• Forecasting
• Humans
• Immunoglobulin G (administration & dosage, therapeutic use)
• Infliximab
• Multicenter Studies as Topic
• Randomized Controlled Trials as Topic
• Receptors, Tumor Necrosis Factor (administration & dosage, therapeutic use)
• Risk Assessment
• Severity of Illness Index
• Time Factors
• Treatment Outcome
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)